Strona 2 - Najlepsi lekarze do leczenia metaplazji żołądka – TOP 61 lekarz

Specjalizuje się w nowotworach układu pokarmowego, ze szczególnym uwzględnieniem leczenia raka żołądka, w tym metaplazji żołądkowej, w szpitalach Valued Med Hub.

• Ponad 10 lat doświadczenia w onkologii klinicznej
• Opublikowane badania dotyczące HER2-dodatniego przerzutowego raka żołądka
• Członek Tureckiego Towarzystwa Onkologii Klinicznej
• Współautor badań nad czynnikami prognostycznymi w leczeniu raka żołądka

Dr Viola Fox kieruje Kliniką Hematologii, Onkologii i Opieki Paliatywnej w BKZ Solingen, specjalizując się w zaawansowanych metodach leczenia nowotworów.

• Specjalizuje się w hematologii, onkologii i immunologii od 2011 roku
• Posiada kwalifikacje w dziedzinie genetyki, co pozwala na rozwijanie spersonalizowanych metod leczenia
• Prowadzi aktywne badania w zakresie biologii molekularnej nad innowacyjnymi terapiami antynowotworowymi
• Jest członkiem niemieckich i amerykańskich towarzystw onkologicznych

Profesor Sebastian Keil specjalizuje się w zaawansowanych technikach radiologii diagnostycznej i zabiegowej, posiadając bogate doświadczenie w obrazowaniu metaplazji żołądka.

• Ukończył z wyróżnieniem Uniwersytet w Würzburgu (Julius-Maximilians-Universität)
• Pogłębiał wiedzę specjalistyczną w Szpitalu Uniwersyteckim w Akwizgranie pod okiem renomowanych profesorów
• Objął stanowisko lekarza naczelnego oddziału radiologii diagnostycznej i zabiegowej w Szpitalu Akademickim w Solingen
• Specjalizuje się w diagnostyce MRI i CT wszystkich obszarów ciała
• Zapewnia pełen zakres usług z zakresu radiologii zabiegowej

Jako kierownik Centrum Nowotworów Układu Pokarmowego, dr Hubert zarządza specjalistyczną jednostką koncentrującą się na złożonych nowotworach układu trawiennego.

• 33 lata doświadczenia klinicznego w onkologii i radioterapii
• Posiada podwójną certyfikację specjalistyczną w dziedzinie onkologii i radioterapii
• Starszy lekarz w Szpitalu Uniwersyteckim Hadassah
• Aktywny członek Izraelskiego Komitetu ds. Nowotworów Układu Pokarmowego
• Wykształcenie obejmuje stopień doktora medycyny (M.D.) oraz dyplom z psychologii

Dr Al specjalizuje się w chirurgii laparoskopowej schorzeń żołądka. Szkolenie medyczne odbył na wydziałach Çapa i Cerrahpaşa Uniwersytetu Stambulskiego.

• Posiada certyfikat specjalisty i ponad 30-letnie doświadczenie chirurgiczne.
• Ukończył zaawansowane szkolenia w zakresie laparoskopowej chirurgii bariatrycznej oraz onkologicznej.
• Odbył staż w zakresie technik laparoskopowej chirurgii antyrefluksowej.
• Wykonuje zabiegi małoinwazyjne, które zapewniają szybszy powrót do zdrowia.

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr Alemdar specjalizuje się w metaplazji żołądka, posiadając solidne zaplecze akademickie zdobyte na Uniwersytecie Akdeniz.

• Certyfikowany specjalista w dziedzinie chorób wewnętrznych i onkologii klinicznej
• Posiada wieloletnie doświadczenie szpitalne, w tym w Szpitalu Uniwersyteckim Akdeniz
• Ekspert w leczeniu złożonych schorzeń układu pokarmowego
• Aktywnie uczestniczy w badaniach naukowych i szkoleniach w szpitalach uniwersyteckich

Profesor Gul Alco posiada ponad 25-letnie doświadczenie specjalistyczne w dziedzinie onkologii radiacyjnej, zdobyte w wiodących tureckich placówkach, takich jak szpital Medipol Acibadem District.

• Ukończyła studia na Uniwersytecie Stambulskim – jednej z najlepszych szkół medycznych w Turcji
• Obecnie zajmuje stanowisko profesora onkologii radiacyjnej na Uniwersytecie Medipol w Stambule
• Posiada doświadczenie jako profesor nadzwyczajny na Uniwersytecie Demiroglu Bilim
• Specjalizuje się w radioterapii nowotworów układu pokarmowego

Specjalizując się w wiroterapii — jednej z najnowszych dziedzin immunologii — dr Jaunalksne stosuje innowacyjne podejścia w klinice Pallas.

• Ponad 30 lat doświadczenia w immunologii
• Kieruje Centrum Immunologii Klinicznej w Szpitalu Uniwersyteckim im. Paulsa Stradiņša
• Absolwentka Ryskiego Instytutu Medycznego, odbyła staż podyplomowy w zakresie chorób wewnętrznych

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.